You’ve successfully taken the risks and done the research to turn your abstract thought into something physically real!

As Robert Redford’s character famously said at the end of The Candidate: “What do we do now?” Transitioning from research to development is the goal of every biotech company, but there are also many common misunderstandings and misconceptions about what this shift entails. The costs (it’s expensive) and timelines (it takes a long time), onboarding new team members, successfully doing both the R and the D at the same time, and regulatory aspects of the change are among the things that must be understood and executed.

Approaching this topic through the lens of today’s difficult funding environment and longer time horizons, panelists will bring a breadth of experiences to detail best practices, answer common (and uncommon) questions, cover anticipated business challenges, and likely tell a few horror stories.